These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27633058)

  • 1. Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel.
    Li K; Mao Y; Lu L; Hu C; Wang D; Si-Tu J; Lu M; Peng S; Qiu J; Gao X
    Int J Oncol; 2016 Oct; 49(4):1679-85. PubMed ID: 27633058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
    Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.
    Yang Z; Chen JS; Wen JK; Gao HT; Zheng B; Qu CB; Liu KL; Zhang ML; Gu JF; Li JD; Zhang YP; Li W; Wang XL; Zhang Y
    J Exp Clin Cancer Res; 2017 Dec; 36(1):178. PubMed ID: 29216925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.
    Cardillo I; Spugnini EP; Galluzzo P; Contestabile M; Dell'Anna ML; Picardo M; Crispi S; Calogero RA; Piccolo MT; Arigoni M; Cantarella D; Boccellino M; Quagliuolo L; Ferretti G; Carlini P; Felici A; Boccardo F; Cognetti F; Baldi A
    Future Oncol; 2013 Sep; 9(9):1375-88. PubMed ID: 23980684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
    Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
    Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
    Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
    Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
    Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
    Hour TC; Chung SD; Kang WY; Lin YC; Chuang SJ; Huang AM; Wu WJ; Huang SP; Huang CY; Pu YS
    Arch Toxicol; 2015 Apr; 89(4):591-605. PubMed ID: 24888374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA polymerase theta repression enhances the docetaxel responsiveness in metastatic castration-resistant prostate cancer.
    Kuei CH; Lin HY; Lin MH; Lee HH; Lin CH; Lee WJ; Chen YL; Lu LS; Zheng JQ; Hung RC; Chiu HW; Chen KC; Lin YF
    Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165954. PubMed ID: 32877750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
    Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
    Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KLF9, a transcription factor induced in flutamide-caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells.
    Shen P; Sun J; Xu G; Zhang L; Yang Z; Xia S; Wang Y; Liu Y; Shi G
    Prostate; 2014 Jun; 74(9):946-58. PubMed ID: 24737412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
    Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
    Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
    Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
    Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer.
    Yun EJ; Zhou J; Lin CJ; Hernandez E; Fazli L; Gleave M; Hsieh JT
    Clin Cancer Res; 2016 Feb; 22(3):670-9. PubMed ID: 26490309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
    Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
    Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
    Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
    Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.